Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Kyle Rabe represents clients in connection with mergers and acquisitions, including public and private acquisitions and divestitures, joint ventures, minority investments, recapitalizations, and private equity transactions. He also advises clients on corporate governance matters.

Mr. Rabe has represented a number of major life sciences companies in connection with buy-side and sell-side mergers and acquisitions transactions. He also represents clients in a variety of other industries, including energy and sports.

  • UCB in its pending $2.1 billion acquisition of Ra Pharmaceuticals, its $1.2 billion sale of Kremers Urban Pharmaceuticals to Lannett, and its acquisition of midazolam nasal spray from Proximagen.
  • Johnson & Johnson in various acquisitions and divestitures, including its acquisition of Olive Medical, acquisition of 3D printing technologies from Tissue Regeneration Systems, sale of Prodisc, and sale of RoC Skincare.
  • Allergan plc in its acquisitions of Kythera Biopharmaceuticals, Bonti, Chase Pharmaceuticals, ForSight VISION5 and Akarna Therapeutics.
  • Abbvie in its $5.8 billion acquisition of Stemcentrx.
  • AstraZeneca in its acquisition of Bristol-Myers Squibb's interests in the companies’ diabetes alliance.
  • Salix Pharmaceuticals in its $2.6 billion acquisition of Santarus, Inc.
  • King Pharmaceuticals, Inc. in its $3.6 billion merger with Pfizer Inc.
  • National Hockey League in negotiating its twelve-year, C$5.2 billion agreement with Rogers Communications for national broadcast and multimedia rights to NHL games, including the Stanley Cup Playoffs and the Stanley Cup Final, in Canada.
  • SK Holdings in its acquisition of a significant minority interest in Eureka Midstream.
  • Leeds Equity Partners in its acquisition of BLR (Business and Legal Resources) and three portfolio companies owned by UCG, LLC (DecisionHealth LLC, Argosy Group LLC and Center for Communications Management Information LLC).
  • Aristocrat Leisure Limited in its $1.28 billion acquisition of Video Gaming Technologies.
  • P. Schoenfeld Asset Management LP (PSAM) in its successful proxy contest to require a renegotiation of the terms of the business combination between MetroPCS and T-Mobile.
  • SandRidge Energy Inc. in its response to a campaign by activist investor TPG-Axon to change control of the SandRidge board of directors.

Previous Experience

  • U.S. Senate Committee on Foreign Relations, Staff Assistant (2005-2006)
  • New York Super Lawyers, Mergers & Acquisitions "Rising Star" (2012-2019)